Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn | -86.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.78% |
| Mar 31, 2026 | 66.11% |
| Dec 31, 2025 | 19.98% |
| Sep 30, 2025 | 45.15% |
| Jun 30, 2025 | 102.96% |
| Mar 31, 2025 | -17.17% |
| Dec 31, 2024 | 152.63% |
| Sep 30, 2024 | 79.35% |
| Jun 30, 2024 | 15.40% |
| Mar 31, 2024 | 10.58% |
| Dec 31, 2023 | -24.84% |
| Sep 30, 2023 | 51.00% |
| Jun 30, 2023 | 6.26% |
| Mar 31, 2023 | -59.37% |
| Dec 31, 2022 | 37.82% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | -32.56% |
| Mar 31, 2022 | 28.79% |
| Dec 31, 2021 | -33.68% |
| Sep 30, 2021 | -23.76% |